Anti-tumor effects of Toxoplasma gondii and antigen-pulsed dendritic cells in mice bearing breast cancer

• DOI: 10.3347/phd.24082
• Publication Date: 2025-02-28T01:33:52Z
• Authors: Bong Kyun Kim; Hei Gwon Choi; Jae-Hyung Lee; In Wook Choi; Jae-Min Yuk; Guang-Ho Cha; Young-Ha Lee
• Keywords: Cancer Immunotherapy; Tumor Antigen

Cancer immunotherapy is widely used to treat various cancers augment the weakened host immune response against tumors. Dendritic cells (DCs) are specialized antigen-presenting that play dual roles in inducing innate and adaptive immunity. Toxoplasma gondii a protozoan parasite exhibits anti-tumor activity certain types of cancers. However, little known about effects T. or tumor/parasite antigen-pulsed DCs (DC vaccines, DCV) breast cancer. In this study, C57BL/6 mice were administered E0771 mouse cancer (Cancer-injected) subcutaneously, Me49 cysts orally (TG-injected), pulsed with cell lysate antigen antigens (DCV-injected) intraperitoneally. Tumor size immunological characteristics subsequently evaluated. We also evaluated matrix metalloproteinase (MMP)-2 MMP-9 levels co-cultured by RT-PCR. The tumor volumes injected (Cancer/DCV-injected mice) similar those Cancer-injected mice; however, they significantly reduced gondii-infected tumor-bearing (TG/Cancer-injected) mice. Moreover, adding (TG/Cancer/DCV-injected compared TG/Cancer-injected IFN-γ, serum IgG2a levels, CD8+ T populations higher DCV- TG-injected than control mice, while no significant differences between Cancer- Cancer/DCV-injected observed. percentage increased TG/Cancer- TG/Cancer/DCV-injected IFN-γ further MMP-2 mRNA expressions decreased live gondii, antigen, (DCV) but not inactivated DCs. These results indicate induces cancer-bearing through induction strong Th1 responses, alone. addition augments gondii.